Fluorodeoxyglucose (FDG) and human epidermal growth factor receptor 2 (HER2) positron emission tomography (PET) scan in breast cancer
- Conditions
- Breast cancerCancer - Breast
- Registration Number
- ACTRN12624000918527
- Lead Sponsor
- Fiona Stanley Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Female
- Target Recruitment
- 10
HER2 positive or HER2 low metastatic breast cancer patient as defined by immunohistochemistry (IHC) measuring cell membrane HER2 protein and/or by in situ hybridisation (ISH) measuring the number of HER2 genes in each cell nucleus. HER2 positivity is defined as either strong (3+) cell membrane staining by IHC or amplification of the HER2 gene by ISH. Participants must be T-Dxd treatment naïve in the metastatic setting. The number of HER2 positive and HER2 low participants included in the study will be capped at five each (e.g. 5 HER2 positive and 5 HER2 low).
Life expectancy less than 6 months, unable to give informed consent, unable to comply with required scanning schedule. May include conditions that increase the risk to the participant, that interfere with the participants ability to give informed consent or interfere with a participant’s ability to comply.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method